Neurodegenerative Disease Market to Reach US$ 128.54 Billion by 2033 at 9.8% CAGR; North America Leads with 41% Share | Key Players AbbVie, Novartis, Roche

The neurodegenerative disease market reached US$ 56.82 billion in 2024 and is expected to reach US$ 128.54 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033. Market growth is driven by the rising global prevalence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, largely due to aging populations and improved disease awareness. Advancements in disease-modifying therapies, biologics, and precision medicine approaches are expanding treatment options and improving clinical outcomes, supporting sustained market expansion.

North America held the largest market share due to advanced healthcare infrastructure, strong investment in neurological research, early adoption of innovative therapies, and high patient awareness. Europe followed with increasing focus on neurological care and supportive reimbursement policies, while Asia-Pacific is expected to witness the fastest growth driven by a growing elderly population, rising disease burden, improving healthcare access, and increasing investments in neurology research and treatment infrastructure across emerging economies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/neurodegenerative-disease-market?sai-v

The neurodegenerative disease market refers to the global industry focused on therapies and treatments for progressive disorders that damage the nervous system, such as Alzheimer's, Parkinson's, and ALS.

Key Developments
✅ January 2026: In North America, increased clinical adoption of next-generation targeted therapies and disease-modifying treatments for Alzheimer's and Parkinson's disease progressed, with notable developments from Biogen, Eli Lilly, and Roche focusing on beta-amyloid, tau, and alpha-synuclein pathways.

✅ January 2026: In Europe, regulatory bodies and healthcare payers refined access and reimbursement frameworks for emerging neurodegenerative therapies, encouraging uptake of novel agents from Novo Nordisk, Lundbeck, and UCB.

✅ December 2025: In Asia-Pacific, research collaborations expanded on gene therapy and neuroprotective small molecules for Huntington's disease and amyotrophic lateral sclerosis (ALS), with progress reported by Ionis Pharmaceuticals, Wave Life Sciences, and PTC Therapeutics.

✅ December 2025: Globally, advancements in biomarker-driven diagnostics and patient stratification tools strengthened early-stage intervention strategies, supported by companies such as Eli Lilly, Roche Diagnostics, and Quest Diagnostics.

✅ November 2025: In Latin America, expanded clinical trial networks improved access to investigational treatments for neurodegenerative disorders, involving partnerships with Biogen, Novartis, and Sanofi.

✅ October 2025: Worldwide, artificial intelligence and machine learning tools enhanced drug candidate identification and repurposing efforts, with contributions from Exscientia, Atomwise, and Recursion Pharmaceuticals.

Mergers & Acquisitions
✅ January 2026: In the United States, Eli Lilly acquired a clinical-stage neuroscience biotech company specializing in disease-modifying therapies for Alzheimer's and related dementias to strengthen its neurodegenerative pipeline.

✅ December 2025: In Europe, Novo Nordisk completed the acquisition of a gene therapy developer focused on neuromuscular and neurodegenerative indications to expand its therapeutic portfolio.

✅ November 2025: In Asia-Pacific, Takeda Pharmaceutical Company acquired rights to a novel small-molecule neuroprotective program to broaden its neurodegenerative disease offerings.

Key Players
AbbVie Inc. | Amneal Pharmaceuticals Inc. | Boehringer Ingelheim International GmbH | F. Hoffmann-La Roche Ltd. | GlaxoSmithKline PLC | Merck & Co. Inc. | Pfizer Inc. | Teva Pharmaceutical | UCB SA | Novartis | Others

Key Highlights
AbbVie Inc. holds 18% share, driven by its strong immunology and specialty therapeutics portfolio, blockbuster biologics, and sustained investment in advanced R&D.

Novartis holds 16% share, supported by leadership in innovative medicines, a diversified specialty drugs portfolio, and strong global commercialization capabilities.

F. Hoffmann-La Roche Ltd. holds 14% share, leveraging precision medicine leadership, robust biologics pipeline, and integrated diagnostics expertise.

Pfizer Inc. holds 13% share, driven by a broad therapeutic portfolio, strong global manufacturing scale, and continuous innovation across chronic and specialty disease areas.

GlaxoSmithKline PLC holds 11% share, supported by its focus on specialty medicines, immunology, and vaccines, along with strategic portfolio realignment.

Merck & Co. Inc. holds 9% share, leveraging leadership in immunology, oncology, and vaccines, supported by a strong late-stage pipeline.

Boehringer Ingelheim International GmbH holds 8% share, driven by strength in respiratory and metabolic diseases and consistent private R&D investment.

Teva Pharmaceutical holds 6% share, supported by its global generics leadership, biosimilar expansion, and cost-efficient manufacturing base.

UCB SA holds 3% share, focusing on neurology and immunology specialty drugs with targeted market presence.

Amneal Pharmaceuticals Inc. holds 2% share, driven by complex generics, specialty product development, and U.S.-focused commercialization.

Others collectively hold 0-5% share, comprising regional and emerging pharmaceutical manufacturers expanding specialty and generic drug offerings.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=neurodegenerative-disease-market?sai-v

Market Drivers
- Rising prevalence of neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS) driven by aging populations.

- Growing demand for effective therapies that slow disease progression and improve quality of life for patients and caregivers.

- Advancements in understanding disease pathology, biomarkers, and genetic risk factors fueling targeted drug development.

- Increasing investment in R&D by pharmaceutical and biotechnology companies focused on novel mechanisms and therapeutic classes.

- Supportive regulatory initiatives in major markets including accelerated approvals and designation pathways for unmet medical needs.

Industry Developments
- Expansion of clinical pipelines featuring disease-modifying therapies, monoclonal antibodies, small molecules, gene therapies, and neuroprotective agents.

- Strategic collaborations between biotech firms, academic research institutions, and pharmaceutical companies to accelerate discovery and clinical translation.

- Growing focus on advanced diagnostics, digital biomarkers, and imaging technologies to enable early detection and patient stratification.

- Adoption of precision medicine and personalized treatment approaches based on genetic profiles and disease subtypes.

- Integration of artificial intelligence, machine learning, and big data analytics to support drug discovery, clinical trial optimization, and real-world evidence generation.

Regional Insights
North America - 41% share: "Driven by high prevalence of neurodegenerative conditions, strong R&D infrastructure, extensive clinical trial networks, and favorable reimbursement environments."

Europe - 28% share: "Supported by robust healthcare systems, increasing investment in neurodegenerative research, and collaborative academic-industry initiatives."

Asia Pacific - 23% share: "Fueled by rapidly aging populations, expanding healthcare access, rising disease awareness, and growing neuroscience research capabilities."

Latin America - 5% share: "Driven by improving neurological care infrastructure, increasing diagnosis rates, and growing healthcare investments."

Middle East & Africa - 3% share: "Supported by emerging healthcare facilities, rising awareness of neurodegenerative disorders, and gradual development of specialty care services."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neurodegenerative-disease-market?sai-v

Key Segments

By Indication Type
Alzheimer's disease represents the largest segment, driven by the growing aging population and rising prevalence of neurodegenerative disorders worldwide. Parkinson's disease holds a significant share due to increasing diagnosis rates and continuous demand for long-term symptomatic management. Amyotrophic lateral sclerosis (ALS) accounts for a smaller but critical segment, supported by unmet medical needs and ongoing drug development efforts. Huntington disease remains a niche segment with focused therapeutic research, while others include multiple sclerosis, epilepsy-related neurodegeneration, and rare neurological disorders.

By Drug Type
N-methyl-D-aspartate (NMDA) receptor modulators play a key role, particularly in Alzheimer's disease management, due to their ability to regulate glutamatergic activity. Selective serotonin reuptake inhibitors (SSRIs) are widely used to manage associated neuropsychiatric symptoms such as depression and anxiety. Dopamine inhibitors and modulators are essential in the treatment of movement disorders, especially Parkinson's disease. Other drug types include cholinesterase inhibitors, monoamine oxidase inhibitors, neuroprotective agents, and emerging disease-modifying therapies.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.